On February 21, Sichuan Kelun Pharmaceutical Co.Ltd(002422) announced that the skb378 / hbm9378 injection jointly developed by Sichuan Kelun Botai biomedical Co., Ltd., the holding subsidiary of the company, and heplatinum pharmaceutical Holding Co., Ltd. (hereinafter referred to as "heplatinum pharmaceutical") obtained the notice of clinical trial from the State Drug Administration and agreed to carry out the clinical trial of skb378 / hbm9378 injection for the indication of moderate and severe asthma.
Skb378 / hbm9378 injection is a class 1 innovative drug with global intellectual property rights, which is jointly developed by Botai biology, platinum medicine utilization and platinum medicine technology platform H2L2 all human mouse. It is an all human monoclonal antibody targeting TSLP (thymic stromal lymphopoietin), Both parties decided that Botai biology and platinum medicine (Shanghai) Co., Ltd. would be the sponsor to promote the clinical research. The results of non clinical studies showed that skb378 / hbm9378 injection had good safety, excellent efficacy and clear mechanism of action.
Up to now, tezepelumab of AstraZeneca / Amgen is the world's leader in the research and development of monoclonal antibodies with the same target. The monoclonal antibody was approved for listing in the United States on December 17, 2021 and is undergoing phase III clinical trials in China. China's konoya, Hengrui and other innovative pharmaceutical enterprises have layout in this target. At present, no similar products have been approved for listing in China.
